MedTrace Logo

Advanced or Recurrent Solid Tumors Treated With SHetA2

NCT04928508 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-05

No results posted yet for this study

Summary

The purpose of this research is to test the safety of the study drug (OK-1) and see what effects (good and bad) this drug has on patients with recurrent solid tumors.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

OK-1

OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated: 5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Debra Richardson, MD · Stephenson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-27
Primary Completion
2026-05-31
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04928508 on ClinicalTrials.gov